We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05341258
Recruitment Status : Completed
First Posted : April 22, 2022
Last Update Posted : August 24, 2022
Sponsor:
Information provided by (Responsible Party):
Gaziosmanpasa Research and Education Hospital

Brief Summary:
Scoring systems (SOFA, APACHE-II etc.) are used to estimate the mortality rates of patients treated in the intensive care unit. . In the scoring systems used, the disfunction level of the organs of the patients is measured. Blood gas analysis is routinely performed in patients whom intubated in the intensive care unit and receiving mechanical ventilation support, and the patient's treatment is optimized according to the results of the examination. The patient's mechanical ventilation settings are regulated by analyzing the Partial Arterial Carbondioxide (paCO2) value in the patient's blood gas result. The difference between the paCO2 value in the blood gas and the End-tidal Carbondioxide (EtCO2) value measured in the mechanical ventilator is 3-5mmHg in normal healthy people, while this difference is seen more in critical care patients. In critically ill patients in the intensive care unit, there is a greater increase in the difference between paCO2 and ETCO2 in cases where mortality is high, such as global perfusion disorder, shock situations, and massive pulmonary embolism, etc. In this study, it was planned to investigate the use of the difference between the paCO2 value in the blood gas taken from the patient and the ETCO2 value measured in the mechanical ventilator to predict the mortality rate of the patient.

Condition or disease Intervention/treatment Phase
Critical Illness Ventilation Perfusion Mismatch Shock Pulmonary Embolism Trauma Copd Diagnostic Test: EtCO2 Diagnostic Test: PaCO2 Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Arterial and End-Tidal CO2 Gradient as a Mortality Predictor in Critical Care Patients
Actual Study Start Date : January 1, 2022
Actual Primary Completion Date : August 1, 2022
Actual Study Completion Date : August 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Critical Care

Arm Intervention/treatment
Critical Care Patients whom intubated last 24 hours
Critical Care Patients whom intubated last 24 hours
Diagnostic Test: EtCO2
EtCO2

Diagnostic Test: PaCO2
PaCO2




Primary Outcome Measures :
  1. Mortality [ Time Frame: 6 months ]
    Evaluation of correlation between PaCO2 and ETCO2 gradient difference and mortality in intubated critical care patients and mortality rates


Secondary Outcome Measures :
  1. ICU Length of Stay [ Time Frame: 6 months ]
    Days patients treated at ICU

  2. Ventilator Free Days [ Time Frame: 6 months ]
    Days during which the patient was mechanically ventilated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Critical Care Patients intubated in last 24 hours.

Exclusion Criteria:

  • Patients younger than 18 years old.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05341258


Locations
Layout table for location information
Turkey
Gaziosmanpasa Training Research Hospital
Istanbul, Turkey, 34255
Sponsors and Collaborators
Gaziosmanpasa Research and Education Hospital
Investigators
Layout table for investigator information
Study Director: Ulku Aygen Turkmen, Proffessor Director of Anesthesiology and Reanimation Department
Layout table for additonal information
Responsible Party: Gaziosmanpasa Research and Education Hospital
ClinicalTrials.gov Identifier: NCT05341258    
Other Study ID Numbers: 3751
First Posted: April 22, 2022    Key Record Dates
Last Update Posted: August 24, 2022
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Embolism
Embolism
Critical Illness
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes